Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-05-30
2006-05-30
Spector, Lorraine (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S007210, C435S007240, C435S091200, C436S501000
Reexamination Certificate
active
07052852
ABSTRACT:
Methods for assessing the risk of developing Alzheimer's Disease (AD), for diagnosing AD, and for measuring the progression of AD in a patient by determining CD45 isoform expression of blood cells obtained from the patient. The methods of the invention include determining CD45 isoform expression by cytometric analysis, quantitative Western immunoblotting, or quantitative RT-PCR or combinations thereof.
REFERENCES:
patent: 5120642 (1992-06-01), Schlossman et al.
Hossein Ghanbari et al., Biochemical Assay for AD7C-NTP in Urine as an Alzheimer's Disease Marker, Journal of Clinical Laboratory Analysis, vol. 12, pp. 285-288 (1998).
Kasra Ghanbari et al., A Sandwich Enzyme Immunoassay for Measuring AD7C-NTP as an Alzheimer's Disease Marker: AD7C Test, Journal of Clinical Laboratory Analysis, vol. 12, pp. 223-226 (1998).
Masanori Utsuyama et al., Different Age-Change in the Numbers of CD4+CD45RA+ And CD4+CD29+ T Cell Subsets in Human Peripheral Blood, Mechanisms of Ageing and Development, vol. 63 (1992), pp. 57-68.
Tero Tapiola et al., Relationship between apoE Genotype and CSF β-amyloid (1-42) and Tau in Patients with Probable and Definite Alzheimer's Disease, Neurobiology of Aging, vol. 21 (2000), pp. 735-740.
Jun Tan et al., Activation of Microglial Cells by the CD40 Pathway: Relevance to Multiple Sclerosis, Journal of Neuroimmunology, vol. 97 (1999), pp. 77-85.
Eric T. Poehlman et al., Energy Expenditure, Energy Intake, and Weight Loss in Alzheimer Disease1-4, Am J Clin Nutr 2000, vol. 72 (suppl), pp. 650S-655S.
I.Skoog et al., A Population Study on Blood-Brain Barrier Function in 85-Year Olds, NEUROLOGY, vol. 50, Apr. 1998, pp. 966-971.
Mikio Shoji, Combination Assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a Biochemical Marker of Alzheimer's Disease, Journal of the Neurological Sciences vol. 158 (1998), pp. 134-140.
A. M. Saunders PhD et al., Association of Apolipoprotein E Allele∈4 with Late-Onset Familial and Sporadic Alzheimer's Disease, NEUROLOGY, vol. 43, Aug. 1993, pp. 1467-1472.
A. M. Saunders et al., Specificity, Sensitivity, and Predictive Value of Apolipoprotein-E Genotyping for Sporadic Alzheimer's Disease, The Lancet, vol. 348, Jul. 13, 1996, pp. 90-93.
Allen D. Roses MD, Apolipoprotein E Genotyping in the Differential Diagnosis, Not Prediction, of Alzheimer's Disease, Annals of Neurology, vol. 38, No. 1, Jul. 1995, pp. 6-14.
R. Motter, MPH et al., Reduction of β-Amyloid Peptide42in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Annals of Neurology, vol. 38, No. 4, Oct. 1995, pp. 643-648.
Bruce H. Price MD, et al., Neuropsychological Patterns and Language Deficits in 20 Consecutive Cases of Autopsy-Confirmed Alzheimer's Disease, Arch Neurol, vol. 50, No. 9, Sep. 1993, pp. 931-937.
Judes Poirier et al., Apolipoprotein E Polymorphism and Alzheimer's Disease, The Lancet, vol. 342, No. 8873, Sep. 18, 1993, pp. 697-699.
Guy McKhann, MD et al., Clinical Diagnosis of Alzheimer's Disease: . . . , NEUROLOGY, vol. 34, No. 7, Jul. 1984, pp. 939-944.
Richard Mayeux MD et al., Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease, The New England Journal of Medicine, vol. 338, No. 8, Feb. 19, 1998, pp. 506-511.
R. Mayeux, Evaluation and Use of Diagnostic Tests in Alzheimer's Disease, Neurobiology of Aging, vol. 19, No. 2, (1998), pp. 139-143.
Zaven S. Khachaturian, PhD, Diagnosis of Alzheimer's Disease, Arch Neurol, vol. 42, No. 11, Nov. 1985, pp. 1097-1105.
Rajesh N. Kalaria, Cerebrovascular Degeneration Is Related to Amyloid-β Protein Deposition in Alzheimer's Disease, Annals New York Academy of Sciences, pp. 263-271, (Sep. 26, 1997).
Ikeda T. Yamamoto et al., Immune System-Associated Antigens on the Surface of Peripheral Blood Lymphocytes in Patients with Alzheimer's Disease, ACTA Psychiatrica Scandinavica, pp. 444-448, (Jun. 1991).
F. Hulstaert, MD et al., Improved Discrimination of AD Patients Using β-Amyloid(1-42)and Tau Levels in CSF, Neurology, vol. 52, May 1999, pp. 1555-1562.
G. R. Hue et al., Peripheral Blood Lymphocyte Subset Distribution and Function in Patients with Alzheimer's Disease and Other Dementias, Aust NZ J Med 1995; vol. 25, pp. 212-217.
Kevin Flurkey et al., Memory T Lymphocyte Hyporesponsiveness to Non-Cognate Stimuli: A Key Factor in Age-Related Immunodeficiency, (Apr. 1992) Eur. J. Immunol. 22(4) 931-935.
Ron Brookmeyer, PhD et al., Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset, American Journal of Public Health, Sep. 1998, vol. 88, No. 9, pp. 1337-1342.
Philip R. Wenham et al., Apolipoprotein E Genotyping by One-Stage PCR, The Lancet, vol. 337, May 11, 1991, pp. 1158-1159.
Stephen W. Hunt III et al., T-Lymphocyte Interactions with Endothelium and Extracellular Matrix, Crit Rev Oral Biol Med, 7(1), (1996), pp. 59-86.
R.C. Petersen, Mild Cognitive Impairment: Transition Between Aging and Alzheimer's Disease, NEUROLOGIA, vol. 15, No. 3, Marzo 2000, pp. 93-101.
Mullan Michael J.
Tan Jun Town
Town Terrence C.
Lockard Jon M.
Roskamp Research, LLC
Spector Lorraine
The Webb Law Firm
LandOfFree
CD45 isoform alteration in CD4 + T cells as a potential... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD45 isoform alteration in CD4 + T cells as a potential..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD45 isoform alteration in CD4 + T cells as a potential... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3584669